Illumina将与Burning Rock一起开发针对中国市场的免疫产品

Illumina公司今天和诊断公司Burning Rock公司一起宣布，他们将一起合作开发针对中国市场的基于Illumina测序设备的免疫产品。

Illumina公司是一家成立于1998年的生物技术公司，2007年收购Solexa公司正式进军基因测序市场。从此之后，Illumina公司成为了世界测序市场中举足轻重的公司。其开发的下一代测序技术，被认为是可以改变生物研究和临床诊断的新兴技术。

作为协议的一部分，Illumina公司将在广州提供NGS设备元件和试剂，这里是Burning Rock公司在中国获得核算提取，文库制备和数据软件分析的地方。

“我们一直在努力促进基因技术在中国的临床应用，”Burning Rock创始人和CEO Yusheng Han在一份申明中这样表示。“基于NGS的免疫分子诊断，包括非侵入性的检测，现在在临床上获得了应用，我们希望能够在医院促进其成为一种标准化的方法。”

Illumina的高级副总裁和首席医疗官Rick Klausner在一份申明中表示，这个合作将增加中国免疫诊断方案的进展。

原文：

Illumina and molecular diagnostics firm Burning Rock announced today that they will codevelop oncology products based on Illumina's sequencing instruments for the Chinese market.

As part of the agreement, Illumina will provide NGS instrument components and reagents and Guangzhou, China-based Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software.

"We have been working to promote the clinical application of genomic technology in China," Burning Rock Founder and CEO Yusheng Han said in a statement. "Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."

The collaboration will "increase access to oncology diagnosis solutions in China," Rick Klausner, Illumina's senior VP and chief medical officer, said in a statement.（转化医学网360zhyx.com）